These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
970 related articles for article (PubMed ID: 34730415)
41. New therapy from old drugs: synergistic bactericidal activity of sulfadiazine with colistin against colistin-resistant bacteria, including plasmid-mediated colistin-resistant mcr-1 isolates. Okdah L; Le Page S; Olaitan AO; Dubourg G; Hadjadj L; Rolain JM Int J Antimicrob Agents; 2018 May; 51(5):775-783. PubMed ID: 29421171 [TBL] [Abstract][Full Text] [Related]
42. Mechanism of Action of Isopropoxy Benzene Guanidine against Multidrug-Resistant Pathogens. Li J; Zhang X; Han N; Wan P; Zhao F; Xu T; Peng X; Xiong W; Zeng Z Microbiol Spectr; 2023 Feb; 11(1):e0346922. PubMed ID: 36475769 [TBL] [Abstract][Full Text] [Related]
43. Combined With Mefloquine, Resurrect Colistin Active in Colistin-Resistant Zhang X; Zhao Y; Feng L; Xu M; Ge Y; Wang L; Zhang Y; Cao J; Sun Y; Wu Q; Zhou T Front Microbiol; 2021; 12():790220. PubMed ID: 34899672 [TBL] [Abstract][Full Text] [Related]
44. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752 [TBL] [Abstract][Full Text] [Related]
45. The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli. Ayerbe-Algaba R; Gil-Marqués ML; Miró-Canturri A; Parra-Millán R; Pachón-Ibáñez ME; Jiménez-Mejías ME; Pachón J; Smani Y Int J Antimicrob Agents; 2019 Oct; 54(4):507-512. PubMed ID: 31299296 [TBL] [Abstract][Full Text] [Related]
46. Bicyclomycin Activity against Multidrug-Resistant Gram-Negative Pathogens. Wang W; Zhu X; Luo H; Wang Z; Hong A; Zeng J; Li L; Wang D; Deng X; Zhao X Microbiol Spectr; 2023 Feb; 11(1):e0379022. PubMed ID: 36533939 [TBL] [Abstract][Full Text] [Related]
47. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections. Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF mBio; 2020 Sep; 11(5):. PubMed ID: 32934086 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821 [TBL] [Abstract][Full Text] [Related]
49. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915 [TBL] [Abstract][Full Text] [Related]
50. Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli. Domalaon R; Okunnu O; Zhanel GG; Schweizer F J Antibiot (Tokyo); 2019 Aug; 72(8):605-616. PubMed ID: 31028351 [TBL] [Abstract][Full Text] [Related]
52. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens. Song M; Liu Y; Huang X; Ding S; Wang Y; Shen J; Zhu K Nat Microbiol; 2020 Aug; 5(8):1040-1050. PubMed ID: 32424338 [TBL] [Abstract][Full Text] [Related]
53. Tan JH; Vidaillac C; Yam JKH; Chua SL; Givskov M; Yang L Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461320 [TBL] [Abstract][Full Text] [Related]
54. Colistin Susceptibility Testing by Colistin Broth Disk Elution MIC Method among Carbapenem-resistant Gram-negative Blood Culture Clinical Isolates in a Tertiary Care Setting, East Delhi, India. Nirmal K; Singh NP; Sarkar K; Goyal N; Gangar S; Dwivedi AN Ethiop J Health Sci; 2023 Sep; 33(5):743-750. PubMed ID: 38784504 [TBL] [Abstract][Full Text] [Related]
55. Chen H; Li H; Liu Z; Li J Microb Drug Resist; 2020 Sep; 26(9):1108-1119. PubMed ID: 32349617 [TBL] [Abstract][Full Text] [Related]
56. Antibacterial effect of rose bengal against colistin-resistant gram-negative bacteria. Kurosu M; Mitachi K; Pershing EV; Horowitz BD; Wachter EA; Lacey JW; Ji Y; Rodrigues DJ J Antibiot (Tokyo); 2023 Jul; 76(7):416-424. PubMed ID: 37076631 [TBL] [Abstract][Full Text] [Related]
57. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. Personne Y; Curtis MA; Wareham DW; Waite RD J Antimicrob Chemother; 2014 Dec; 69(12):3236-43. PubMed ID: 25134721 [TBL] [Abstract][Full Text] [Related]
58. Relationship Between Biofilm Formation and Antimicrobial Resistance in Gram-Negative Bacteria. Cepas V; López Y; Muñoz E; Rolo D; Ardanuy C; Martí S; Xercavins M; Horcajada JP; Bosch J; Soto SM Microb Drug Resist; 2019; 25(1):72-79. PubMed ID: 30142035 [TBL] [Abstract][Full Text] [Related]
59. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E.coli and Klebsiella pneumoniae by checkerboard method. Dhandapani S; Sistla S; Gunalan A; Manoharan M; Sugumar M; Sastry AS Indian J Med Microbiol; 2021 Jan; 39(1):6-10. PubMed ID: 33516606 [TBL] [Abstract][Full Text] [Related]
60. Carbapenem-resistant gram-negative bacterial infections and risk factors for acquisition in a Kenyan intensive care unit. Maina JW; Mutua JM; Musyoki AM BMC Infect Dis; 2024 May; 24(1):522. PubMed ID: 38783175 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]